FDA/EMA Dosing Regimens for JAKi Use for Pediatric Indications

Name: FDA/EMA Dosing Regimens for JAKi Use for Pediatric Indications
Creator: Marc Hill
Published: 2026-03-18T07:18:05.367Z
Keywords: Pediatric Dermatology, Alopecia Areata, Janus Kinase

Hill, Marc; Irfan, Mahwish; Bergfeld, Wilma; Piliang, Melissa

doi:10.17632/rfjr6jkh6k.1

FDA/EMA Dosing Regimens for JAKi Use for Pediatric Indications

Published: 18 March 2026| Version 1 | DOI: 10.17632/rfjr6jkh6k.1

Contributors:

,

Description

This table summarizes the recommended dosing regimens for JAK inhibitors approved for pediatric indications by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Files

Institutions

Case Western Reserve University
Ohio, Cleveland
Cleveland Clinic
Ohio, Cleveland

FDA/EMA Dosing Regimens for JAKi Use for Pediatric Indications

Description

Files

Institutions

Categories

Licence